Article By:
AO Markets
Monday, December 5, 2016 9:21 AM EDT
Juno Therapeutics posted positive preliminary results in patients with ibrutinib-refractory Chronic Lymphocytic Leukemia — CLL. These results were presented at a medical conference at the 58th American Society of Hematology.
Biotech is Hot Sparked By Biotech M&A Deals for Juno and Bioverativ
I can't believe how high $JUNO has gone up since I've sold it. Big mistake.
Juno Therapeutics Shares Sky Rocket Following Buyout For $9 Billion
I can't believe I used to own this stock. Sold too soon! $JUNO
Biotech Buzz Is Broken
$KITE opened pretty good, $JUNO needs a bounce